Circadian variation in bone resorption is not related to serum cortisol.
Serum osteocalcin, serum procollagen type I carboxyterminal propeptide (sPICP), and the urinary excretion of pyridinium crosslinks (biochemical markers of bone formation and resorption) all exhibit a circadian variation with a peak during the night. This study was performed to investigate the influence of the endogenous circadian rhythm in cortisol on the biochemical markers of bone turnover. Participants included 11 patients substituted with hydrocortisone due to either hypopituitarism (n = 7) or bilateral adrenalectomy (n = 4). Their daily tablet intake of hydrocortisone was divided in four equal doses in order to abrogate the known circadian variation in cortisol. 24 healthy postmenopausal women served as controls. The study design was performed over 24 h, with blood samples taken every 3 h, and urine collected in 3 h aliquots. Urinary pyridinium crosslinks (Pyr/ Cr, D-Pyr/Cr), serum osteocalcin (sOC), and serum PICP were measured. Patients without a circadian variation in cortisol had normal circadian variation in the urinary excretion of pyridinium crosslinks and sPICP, but no circadian rhythm in serum osteocalcin. We conclude that the etiology of the circadian rhythm in the biochemical markers of bone turnover is still unknown. This study indicates that the circadian variation in sOC can be controlled by the endogenous circadian variation in serum cortisol, whereas this hormone does not control the circadian variation in either the serum PICP or the urinary excretion in pyridinium crosslinks.
Schlemmer
A
A
Center for Clinical and Basic Research, Ballerup, Denmark.
Hassager
C
C
Alexandersen
P
P
Fledelius
C
C
Pedersen
B J
BJ
Kristensen
I O
IO
Christiansen
C
C
D000315:Adrenalectomy; D001862:Bone Resorption / Q000097:blood* / Q000503:physiopathology; D002851:Chromatography, High Pressure Liquid; D002940:Circadian Rhythm / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000097:blood* / Q000494:pharmacology / Q000627:therapeutic use*; D007018:Hypopituitarism / Q000188:drug therapy; D008297:Male; D015675:Osteocalcin / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D017698:Postmenopause; D011347:Procollagen / Q000097:blood; D011726:Pyridinium Compounds / Q000652:urine; D012015:Reference Standards
D010446:Peptide Fragments; D011347:Procollagen; D011726:Pyridinium Compounds; C042813:procollagen type I carboxy terminal peptide; D015675:Osteocalcin; D006854:Hydrocortisone